Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

Abstract Background Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect...

Повний опис

Бібліографічні деталі

Автори:	J. David Smeijer, Donald E. Kohan, Peter Rossing, Ricardo Correa-Rotter, Adrian Liew, Sydney C.W. Tang, Dick de Zeeuw, Ron T. Gansevoort, Wenjun Ju, Hiddo J. Lambers Heerspink
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2023-09-01
Серія:	Cardiovascular Diabetology
Предмети:	Insulin resistance Atrasentan Endothelin receptor antagonist Chronic kidney disease Type 2 diabetes
Онлайн доступ:	https://doi.org/10.1186/s12933-023-01964-8
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!